Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9Breast 7Gynecologic 3Tumor-Agnostic 2Thoracic 2Other hematologic neoplasm 2Head & Neck 2NET 1Lymphoid 1Endocrine 1Dermatologic 1Classical hematology 1

Conditions

Keratosis, Actinic 1Disease 1

Interventions

pembrolizumab 65Nivolumab 59Ipilimumab 33Cyclophosphamide 23Specimen Handling 16Magnetic Resonance Spectroscopy 15Biopsy 15relatlimab 13fludarabine 13cemiplimab 13Opdualag 12Blood Specimen Collection 11binimetinib 10aldesleukin 9Radiosurgery 9Interleukin-2 9encorafenib 8atezolizumab 7Immunotherapy 7tebentafusp 6mogamulizumab 6fludarabine phosphate 6Temozolomide 6Surgical Procedures, Operative 6Paclitaxel 6Immunoglobulin G 6CTLA-4 Antigen 6Aminolevulinic Acid 6Radiotherapy 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Control Groups × Dermatologic × Clear all
NCT07335003 2026-01-12

Study of the Photoprotection and Prevention of Actinic Damage With Anthelios Fluide 100 KA+ UVMune 400 in Patients With Multiple Actinic Keratoses

Cosmetique Active International

Phase NA Recruiting
80 enrolled
Dermatologic

Disease, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡